Research programme: skin cancer therapeutics - Cipher Pharmaceuticals

Drug Profile

Research programme: skin cancer therapeutics - Cipher Pharmaceuticals

Alternative Names: ISC 4; MXO-005; Nanolipolee-007; PB 1SC; Sela-1-GSH; Selanocoxib

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Penn State Research Foundation
  • Developer Cipher Pharmaceuticals
  • Class Amines
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Mitogen-activated protein kinase inhibitors; Proto oncogene protein b raf inhibitors; STAT transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma
  • No development reported Skin cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-cancer in Canada
  • 09 Jan 2015 Cipher Pharmaceuticals acquires all assets, including seven preclinical compounds for the treatment of Malignant melanoma and other Skin cancers from Melanovus Oncology
  • 09 Jan 2015 Cipher Pharmaceuticals has patent protection for compounds for the treatment of Malignant melanoma and other Skin cancers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top